preclinical white papers and articles
-
New Approaches To Antifungal Therapies Hope To Push New Drugs To Market In The Near Future
8/2/2021
Millions of fungal species live in soil, grow on plants, not to mention on our bodies. Every inhalation can introduce fungal spores. To find out how this happens, read the available blog post.
-
Gene Therapy Startup Uses Horses To Test Possible Osteoarthritis Therapy
8/2/2021
Osteoarthritis is a debilitating and painful wearing down of joint cartilage tissues. Every year, more than three million people in the U.S. (and millions more worldwide) are diagnosed with the disease. Read the available blog to find out more.
-
New Eye Color Genetics Research Could Revolutionize Eye Disease Treatment
8/2/2021
A new study cited in Science Daily suggests that the genetics of human eye color may be much more complex than previously thought. Interestingly, this study could have implications that go far beyond eye color.
-
A CRO's Way Forward In The Midst Of A Pandemic: QPS Operations And COVID-19
6/18/2021
In this Q&A, QPS Holdings LLC Chairman President, and CEO, Ben Chien, Ph.D., reflects on the progress of the company’s growth from a small, three-person start-up to a mid-sized CRO, the impact COVID-19 has had on drug development and clinical trials, and the way forward for CROs in the midst of a pandemic.
-
The Most Effective COVID-19 Vaccine Could Be Intranasal
6/17/2021
Vaccine developers are looking at preventing the coronavirus from being transmitted by focusing on the nose and respiratory tract. An intranasal vaccine would trigger immune responses in the nose, throat and lung mucosa by targeting immunoglobulin A (IgA), antibodies which exist solely in the mucosa. The mucosa acts as a physical barrier to potential pathogens, trapping them before they have a chance to enter the body. Given this, the intranasal vaccine would prevent transmission from exhaled droplets or aerosols, as there would not be virus in the body to exhale.
-
Covid-19 And Brain Fog: How Some Infections Affect The Neurological System
6/17/2021
Difficulty thinking, concentrating, and remembering are amongst the most debilitating long-haul symptoms of COVID-19. In some cases, this “brain fog” can linger for months. New research helps explain how SARS-CoV-2, the virus that causes COVID-19, spreads to the brain and why some patients experience severe neurological symptoms while others do not.
-
New Insight Into RNA And DNA Relationship Could Lead To New Antivirals
6/13/2021
RNA viruses are known to cause a large number of diseases in humans, including COVID-19. One potentially valuable drug development avenue is identifying a mechanism that could halt the function of viral RNA polymerase (RNAP) — the enzyme that initiates RNA replication and thus propagates RNA viruses. In this blog review how a team from the University of Turku, Finland, and Penn State University discovered not only how viral RNA polymerase is triggered, but also how it avoids using DNA nucleotide building blocks, which are chemically similar to RNA.
-
COVID-19 Vaccine Development: Building On A Legacy Of Innovation
3/31/2021
The SARS-CoV-2 virus at the center of the COVID-19 pandemic may be novel, but the coordinated research and development efforts to create a vaccine for it are not entirely so. They borrow from experiences derived from more than 50 years of successful vaccine development programs. Read Worldwide’s take on the history of medicine and the development of the coronavirus vaccine.
-
Pathology’s Best-Kept Secret
3/25/2021
Chief Pathologist John Cochran discusses how clinical trials offer pathologists the opportunity to work at the forefront of diagnostic discovery.
-
Elevating Effective Outcomes With Companion Diagnostics
3/22/2021
Companion diagnostics (CDx) is a keystone for pharma to create more precise drug therapies as personalized medicine accelerates. Here’s why a CDxcentral laboratory partner is necessary.